Nader Francois 4

What Happened

• Nader Francois, a director of Moderna (MRNA), reported the conversion/vesting of restricted stock units into 12,174 shares on April 30, 2026. The Form 4 also shows a simultaneous disposition of 12,174 shares with $0 proceeds.
• The filing lists the acquisition as a derivative conversion (code M) and the disposition also as a derivative transfer at $0. No cash value or sale proceeds are reported for these transactions.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (timely — within the usual 2 business-day reporting window).
• Acquired: 12,174 shares via conversion of RSUs (price N/A).
• Disposed: 12,174 shares, $0 proceeds (derivative).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — RSUs convert into common stock on a one-for-one basis. F2 — The RSU award vested in full on April 30, 2026.
• Transaction code M indicates exercise/conversion of a derivative (here, RSU conversion).

Context

• This event reflects RSU vesting/conversion rather than an open-market purchase or a sale. The equal-sized disposition at $0 commonly represents shares withheld or transferred to satisfy tax obligations or administrative requirements, not a market sale; the filing itself does not report cash proceeds from a sale.
• Such administrative transfers after vesting are routine and do not necessarily indicate a change in the insider’s view of the company.